Helping people in need !!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ATHX is going to remain in business a lot longer now that the underwriting of the 13,000,000 shares has been completed last week. The underwriting was effective and it signals the deal was done. Fees was paid to underwriters and felt the need for capital was the primary concern with money flow into this company. Let's not forget regarding the short mafia might deserting their course rather than see additional funding extend the life of the company, even if the company fails, it's still a positive delay. The negative chatter about restrictions of public offerings to 30 / 33% of the outstanding, is negative, as it hand ties the fund raising efforts of the current management before even knowing the current pressing situation. There probably a lot of ?????????????? the volatility of the stock, the above items could easily influence the price, especially because of the light volume. The good news that the shares price have maintained a okay performance ... GOOD LUCK LONGS
Sarah Busch is starting a new position as Vice President, Regenerative Medicine and the head of business development and it happened 3 weeks ago ... It Seems they are doing internal work which would indicate they are planning to stay in business. Doesn't mean there isn't a dilutive capital raise coming down the line... I believe they must have a partnership deal with funding in the works if they made a move like this going forward. They also made some changes regarding other promotions during this quarter. Does that sound like a company ready to close their doors?? I think not and the reason will reveal itself soon!! News should be coming, and the shorts will be running ... Good Luck Longs
Check out the recent New Corp. Fact Sheet that came out a couple of days ago ... The ESG presentation hasn't been updated since Aug. 2022 Check it out ... GOOD LUCK LONGS
https://s23.q4cdn.com/674737627/files/doc_downloads/factsheet/2023/2023-Corporate-Fact-Sheet.pdf
Something else is brewing regarding Japan's Kyocera pulling out of Australia's Regeneus deal for stem cell therapy Progenza for osteoarthritis which ATHX seems to be in play ...
News of the deal falling apart is a particular blow to Regeneus, because it saw the deal as a validation of its technology, and it specifically chose the Japan market as its entry point because it believed it would quickly gain approval and be able to commercialize the product in other territories. Under the terms of the deal, Regeneus, of Sydney, was to receive $19 million in up-front and milestone payments, consisting of $9 million up front and $10 million in regulatory and development milestones. Regeneus would have also received double-digit royalties on sales and retained rights to negotiate licenses with other partners for additional indications inside and outside of Japan.
Check out Athersys' leadership page on the company's website which has been updated. The timing regarding of the announcement is positive. Dan has been AVOIDING any mention of a partnership until it is a done deal, something that could happen VERY soon. Get your ????? in order which they are inviting people to submit ??????????? .... GOOD LUCK LONGS
I'm thinking a short-term solution that Mitsubishi, which has demonstrated A LOT of interest in MS for ARDS in Japan, would LOVE to get more exposure in many other countries along with the Marketing rights etc. including being a shareholder along with Helios. They have done PLENTY of due diligence Regarding MS a Mitsubishi partnership would be HUGE which they are sold on the merits, and they would also venture further. With more trial result in store this is a SLAM DUNK ... GOOD LUCK LONGS
According to the ST moving average the 30-60 days and this is the Yahoo Chart Service, which has turned positive with the closing price today .... This is taking out the previous high of $1.36 few weeks ago. The stock price is higher than two the MA's mentioned and the current trend in place which points to a 30-day MA, up through the 60-day MA, in a week to ten days' time. This will not go unnoticed among technicians and avid stock watchers .... GOOD LUCK LONGS
Athersys Inc $ 1.21
ATHX 0.09
Short Squeeze Ranking™ view
Daily Short Sale Volume view
Short Interest Ratio (Days To Cover) 0.6
Short Percent of Float 2.41 %
Short % Increase / Decrease -27 %
Short Interest (Current Shares Short) 389,600
Shares Float 16,150,000
Short Interest (Prior Shares Short) 533,300
% From 52-Wk High ($ 3.39) -64.31%
% From 50-Day MA ($ 0.92) 31.04%
% From 200-Day MA ($ 0.87) 38.31%
% From 52-Wk Low ($ 0.13) 830.77%
52-Week Performance 45.78%
Trading Volume - Today vs Avg 45.74%
Trading Volume - Today 307,866
Trading Volume - Average 673,100
Market Cap. 268,728,900
% Owned by Insiders 7.39%
% Owned by Institutions 22.20%
Exchange NAS
Record Date 2023-JanA
Get ready for a bidding war!!! Ask yourself who wouldn’t be interested in a Phase 3 for stroke that is OVER 50% enrolled .... The NEW guy Joe Nolan was brought on which may know some INTERESTED players… Dan has a plan regarding a partnership which he kind of mention's it in his last sentence in today's PR paragraph. Mitsubishi reflects growing interest along with LARGER companies in the likes of (PLURAL) in MultiStem. Dan also commenting on an announcement last month made by Healios, Dan was encouraged by Healios’ recent letter of intent to establish a NEW company for the joint development of MultiStem for acute respiratory distress syndrome, or ARDS, with investment from Mitsubishi UFJ Capital which he believes their partnership will continue momentum in clinical development with ALOT of growing interest.... GOOD LUCK LONGS
https://finance.yahoo.com/news/athersys-provides-multistem-clinical-133000621.html
Stop and think about the market cap regarding Healios it's ONLY been 3 or 4 times that of Athersys. The current market cap of Healios is $120M, and Athersys is only $15M ... Do the math especially when Athersys gets a partnership deal it should have been at $38-$48 million instead and NOT 15M if NOT for the current financial crisis. The company is facing delisting unless they get their share price above 2 and their market cap above 34M which they would also ask for an extension. The odds that happening is second to none with a partner ... Let's NOT forget that Dan has stated that there will be a partnership deal coming sometime soon. I say NO LATER by the end of March which WILL provide PLENTY of funding going forward for M2 results Etc. .... GOOD LUCK LONGS
Athersys to present at Advanced Therapies Week, January 17-20 2023, Miami Florida
News
Day 1 - 18 Jan 2023: What Does A Global Supply Chain Look Like for CGT? Defining End-To-End Logistics
11:05am Presentation: The Last Mile to the Patient in Cell Therapy
The supply chain for cell and gene therapy will need to mature and scale significantly to meet the potential commercialization pipeline of the therapies in development today
While all areas of the end to end supply chain have room for improvement, the last mile to the patient is particularly challenged, due to the unique needs in ultracold logistics and limited capacity at clinical sites.
In this presentation, we will summarize the challenges and present new models and technologies that we have explored and developed to support the last mile to the patient for larger-scale allogeneic cell therapies. These ideas should also be relevant for autologous therapies and other players in the cryo logistics space.
Maia Hansen, Chief Operating Officer, Athersys
https://advancedtherapiesweek.phacilitate.com/stream/what-does-a-global-supply-chain-look-like-for-cgt-defining-end-to-end-logistics
New filing which Dan bought 100,000 shares ... GOOD LUCK LONGS
https://www.athersys.com/investors/financial-information/sec-filings/sec-filings-details/default.aspx?FilingId=16218393
The rising GLOBAL burden of STROKE a Professor Valery Feigin from New Zealand was interviewed at the recent World Stroke Congress in Singapore emphasizes the importance of stroke prevention. His OWN words explained the increasing severity of stroke challenges worldwide. He mentioned in the last 30-40 years, there has been an unprecedented growth in stroke burden and stroke has tripled in the past few decades, with the highest burden in lower-income and lower-middle-income countries.
This is ALREADY a BIG concern If NOT addressed, which it will keep on increasing as time goes on resulting in an unmanageable strain on global health services ... GOOD LUCK LONGS
Preview to the ATHX conference, they will be posting a $2.00 per share loss which is a little less thought ... Also, Helios is claiming ATHX has broken agreement for assistance and supplies, which I'm guessing regarding Multistem. ATHX is protesting and negotiating with a contract manufacturer, hopefully to be successful and work out a deal. Stop and think of the delay in the meeting which might have been to prep the street for the magnitude of the loss, as they have now done. Everyone was thinking the loss per share would have been a BIGGER number, because the rev-split lowered the number of shares and increased the loss per share. This should wake everyone up going forward and the short interest has also dropped ... GOOD LUCK LONGS
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221111:nBwbbStvPa
Dan MUST have a deal in hand and is planning for the future ...According to the Cooperation Agreement from Feb. 2021, Healios can own up to 9.9% of Athersys shares. See the Comprehensive Framework Agreement from Aug. 2021:
https://www.sec.gov/Archives/edgar/data/1368148/000134100421000268/sc13d-a10.htm
The Framework Agreement also states that "Healios retains the right to appoint one nominee for election to the Issuer’s Board of Directors if Healios beneficially owns 5% or more of the Issuer’s outstanding shares of Common Stock. Dr. Kagimoto, Chairman and Chief Executive Officer of Healios, currently serves on the Issuer’s Board of Directors as the Healios designee." Healios ownership either went beneath the 5% threshold or will get there soon. According to the March 2018 agreement:
"during such time as Healios beneficially owns less than 15.0% but 5.0% or more of the Company’s outstanding common stock, the Board will nominate one of Healios’ nominees suitable to the Company to become a member of the Board at each annual election of directors."
https://www.sec.gov/Archives/edgar/data/1368148/000119312518085897/d551745d8k.htm
Healios owned 16,310,526 shares pre-RS which should be 652,421 post-RS.
The number of the outstanding shares is currently close to 13 million.
This is ALLLLLLLLL speculation IF and when Healios has the right to select a board member regarding Traub ... Which is NO GREAT LOSS ... GOOD LUCK LONGS
Dr. Osanai - Multistem Stroke Therapy 40th Annual Meeting of the Japanese Society of Neurotherapy to be held from November 2nd to 4th, 2022 ... GOOD LUCK LONGS
https://www.reddit.com/r/ATHX/comments/yhxj01/dr_osanai_multistem_stroke_therapy/?%24deep_link=true&correlation_id=1a7806bf-1623-4115-8d85-d6e0e22f1524&post_fullname=t3_yhxj01&post_index=1&ref=email_digest&ref_campaign=email_digest&ref_source=email&utm_content=post_title&%243p=e_as&_branch_match_id=829669447967134701&utm_medium=Email%20Amazon%20SES&_branch_referrer=H4sIAAAAAAAAA22QzWrDMBCEn8a9OYkl2w2FUAKl9AF66G1RrXW8if6Q1jh5%2B66b5laQ0PANM7toYk7lZbvNaC3xxqS0cRQuW51eK9XqdEAw5UlkzHSiYBzM2R2mNVXpY6Xe5SzLsvnLD9ELyHKPnx9f8gjwGLiIvE3X864RYTPEYoIh8LNjKoweCud4QeAJs0m3tVdLdWsRE6wLVfqN84yV6oeYMzrDFAOQFd6Y5%2F2u%2Fx7rple6bpumq%2Fd239W2xx0qNTadaiWXYmEYZ%2BeC8bjWaXhsdPcoWLyufQIyjqLQG3Jg6YSF7xAG45OhU%2FjfLXHOAz48gTN7GGJg%2BQKhv2OY2OEPvMOjdXcBAAA%3D
https://worldstrokecongress.org/register/ ... GOOD LUCK LONGS
This posting was added just hours ago and already has 23 applicants which is getting ALOT of TRACTION for a small company. Chief Medical Officer Chief Financial Officer
The new CFO will most likely replace the interim CFO (Kasey Rosado) and will cost less. As for the CMO - Dr. Eric Jenkins is supposed to be Vice President Clinical Development and Medical Affairs at Athersys but his name was removed from the Management Team page a month ago so maybe he is leaving too .... GOOD LUCK LONGS
https://www.linkedin.com/jobs/view/3310960779/?refId=qKJvIWTR5UZgzLOm1YLNDw%3D%3D&trk=d_flagship3_company
https://www.linkedin.com/jobs/view/3310963081/?refId=qKJvIWTR5UZgzLOm1YLNDw%3D%3D&trk=d_flagship3_company
GOOD THINGS RRRRRRRRRRRR HAPPENING ... GOOD LUCK LONGS
THE SHORTIES RRRRRR AT IT AGAIN its increased by 58% from 539,819 to 851,000 ... It WILL add MORE FUEL for the LIFTOFF when OUR time comes ... GOOD LUCK LONGS
https://shortsqueeze.com/?symbol=athx
Transcript : Athersys, Inc. - Special Call
10/06/2022 | 04:00pm
https://www.marketscreener.com/amp/quote/stock/ATHERSYS-INC-431073/news/Transcript-Athersys-Inc-Special-Call-41945896/
The SHORTS rrrrrrrr at it AGAIN ... 2.25m traded at 8:20
Pre-Market: 5:06AM EDT 2.7200 +0.5300 (+24.2009%)
X My break even is $26.50 ... lol Pre-Market: 4:31AM EDT ATHX ... 2.5100 +0.3200 (+14.6119%)
X ... Hopefully a rally or a buy out will happen sooner than later .. I'm with U my break even is $25.50 which I have 400k invested ... GOOD LUCK
The SHORT PANTS RRRRRRRRR at it AGAIN !!!!!!!!!!! They WILL be COVERING SOONER than LATER ....
NICCCCCEEEEEEEEEEEEEEEEEEEEEEEEE
Ducky went back to the farm ... TOOOOOOOO FUNNY
It should be noted that this sum $12.8 million is not expected to be received before 2030 (if at all). According to the amended agreement, the purchasers can exercise 2 million warrants at a price of $6.385 until February 17, 2030:
2 million warrants X $6.385 = $12.77 million.
But is unlikely that they will exercise these warrants before the end of the exercise period unless 3 conditions are met: The warrant is in-the-money (the stock price is higher than $6.385) The stock price is expected to rise, which the stock price was expected to fall. On the other hand, we can expect Athersys to raise more money early next year, as it is pointed out here.
The full text of the article:
https://old.reddit.com/r/ATHX/comments/xlxgfl/pr/ipm5y3p/
This shows additional confidence on the part of the investor, also shows that ATHX management has lined up additional sources of borrowing or financing ... It's a pro-active move.
https://www.athersys.com/investors/press-releases/press-release-details/2022/Athersys-Amends-Securities-Purchase-Agreement-in-Connection-with-Recent-Registered-Direct-Offering/default.aspx
Athersys issues 840k additional shares for employee incentives and compensation .... https://quantisnow.com/insight/3427272
Athersys and Healios to present at the 2022 Cell & Gene Meeting on the Mesa, Carlsbad, CA, October 11, 2022 5:00pm – 5:15pm: Healios - Richard Kincaid, Executive and Chief Financial Officer (In-person Presentation) GOOD NEWS AHEAD ... GOOD LUCK LONGS
https://meetingonthemesa.com/agenda
THE SHORT PANTS RRRRRRR PLAYING THEIR USAUL FRIDAY/ WEEKLY ROUTINE ... PUT ALLLLL UR SHARERS WAY ABOVE MARKET PRICES SOOOOOO THEY WILL NOT BE ALBE TO USE WHAT UUUUUUU HAVE .... THEY WILL PAY THE PRICE ... GOOD LUCK LONGS!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!